The author of a study that found two diabetes drugs may double the risk of a dangerous pancreas inflammation says his findings show a need for more research into the subject.
Bloomberg has reported on the study, which found that Merck’s diabetes drug Januvia and Bristol-Myers Squibb’s Byetta may double a user’s risk of pancreatitis.
The story says both drugs increase GLP-1, which is a hormone that stimulates insulin production from the pancreas.
Bloomberg quotes Sonal Singh, an assistant professor of medicine at ...
continue reading...